文献速递胸部肿瘤

HER2靶向治疗晚期HER2突变NSCLC的疗效与安全性:系统综述与Meta分析

Efficacy and Safety of HER2-Directed Therapies for Advanced HER2-Mutant NSCLC: A Systematic Review and Meta-Analysis.
PubMed 文献 · J Thorac Oncol · 2026-09-28

该系统综述与Meta分析纳入7项前瞻性试验共916例晚期HER2突变NSCLC患者,比较HER2 TKIs与ADCs的疗效与安全性。汇总ORR为TKIs 65%(95%CI 61%-69%)、ADCs 57%(95%CI 52%-61%);YVMA插入突变者TKIs ORR 74%、ADCs 57%。ADCs≥3级不良事件发生率更高,提示TKIs可能为优选初始方案。

要点

  • HER2 TKIs汇总ORR 65%,高于ADCs的57%
  • YVMA插入突变者TKIs ORR 74%,ADCs 57%
  • ADCs≥3级不良事件发生率高于TKIs

核心结论

  • 在晚期HER2突变NSCLC中,HER2 TKIs可能较ADCs更适合作为初始治疗选择,因其缓解率更高、安全性更优且TKI后ADC疗效似可维持。

研究设计与样本

  • 系统综述与Meta分析,检索多个生物医学数据库,纳入评估至少在一国获批的HER2 TKIs与ADCs的前瞻性试验,共7项试验916例患者,采用固定效应模型。

主要发现

  • HER2 TKIs汇总ORR为65%(95%CI 61%-69%),ADCs为57%(95%CI 52%-61%)。
  • HER2 Y772_A775dupYVMA插入突变者中,TKIs的ORR为74%,ADCs为57%。
  • 非YVMA插入的酪氨酸激酶域突变者中,TKIs与ADCs的ORR分别为57%和60%。
  • 非酪氨酸激酶域突变者中,TKIs与ADCs的ORR分别为31%和33%。
  • ADCs的≥3级不良事件发生率高于TKIs。

临床怎么用

  • 对于晚期HER2突变NSCLC,尤其YVMA插入突变者,可优先考虑HER2 TKIs作为初始治疗。
  • TKI治疗后仍可保留ADC治疗选择,因ADC在TKI暴露后疗效似可维持。

局限性

  • 证据主要来自单臂试验,样本量有限,缺乏直接比较数据。
  • HER2靶向治疗的首选方案及序贯策略仍需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recently, both human epidermal growth factor receptor (HER2) tyrosine kinase inhibitors (TKIs) and antibody-drug conjugates (ADCs) targeting HER2 have reported clinically meaningful activity and received regulatory approval for advanced HER2-mutant NSCLC, although the evidence is primarily derived from single-arm trials with modest sample sizes and a lack of direct comparative data. The preferred choice and sequencing of HER2-directed therapy, particularly across distinct clinical contexts, require further studies. We searched multiple biomedical databases for prospective trials evaluating the efficacy and safety of HER2 TKIs and ADCs approved in at least one country for advanced HER2-mutant NSCLC. The primary outcome was objective response rates (ORRs). Secondary outcomes included ORRs in prespecified subgroups, progression-free survival, and adverse events. Meta-analyses were performed using a fixed-effect model. A total of 916 patients from seven trials were included in the analysis. The pooled ORR was 65% (95% confidence interval: 61%-69%) for HER2 TKIs and 57% (95% confidence interval: 52%-61%) for ADCs. In patients with HER2 Y772_A775dupYVMA insertion, ORRs were 74% with TKIs and 57% with ADCs; in those with non-YVMA insertion tyrosine kinase domain mutations, ORRs were 57% and 60% with TKIs and ADCs, respectively; and in those with non-tyrosine kinase domain mutations, ORRs were 31% and 33% with TKIs and ADCs, respectively. The ORR in those with TKI and prior ADC exposure seemed diminished, whereas ADC efficacy seemed maintained after TKI treatment. Notably, ADCs were associated with a higher incidence of grade 3 or higher adverse events than TKIs. The findings suggest that HER2 TKIs may be the preferred initial option over ADCs in advanced HER2 mutated NSCLC, given their higher response rates, particularly in patients with YVMA insertions, a more favorable safety profile, and preserved ADC efficacy after TKI exposure. Prospective validation is warranted.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Li MSC, Soon YY, Au-Yeung PY, et al. Efficacy and Safety of HER2-Directed Therapies for Advanced HER2-Mutant NSCLC: A Systematic Review and Meta-Analysis. J Thorac Oncol. 2026. PMID: 42805461. doi:10.1016/j.jtho.2026.106129

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。